CJC-1295 is a commonly searched research peptide, most often encountered as part of a CJC-1295 with Ipamorelin combination. The questions to settle before ordering are the familiar ones: what is it, what does its documentation establish, and what is the regulatory context in Canada. This is a source-based summary. It is not a guide to any use, not a claim that CJC-1295 is an authorized drug or suitable for human use, and not legal or medical advice.
Identity starts with the named compound
CJC-1295 is a synthetic analogue of growth-hormone-releasing hormone (GHRH) — a 30-amino-acid peptide built on a modified GHRH(1–29) (sermorelin) base. A widely referenced form, CJC-1295 DAC, adds a drug affinity complex (DAC) that binds albumin and, in that form, has been described with an estimated half-life of about six to eight days; that long-acting property is the main reason the compound is discussed separately from shorter GHRH fragments. A procurement record should begin with the compound name, whether the DAC form is intended, the selected strength, and the lot, so a receiving laboratory can reconcile what was ordered against the label and the source document. Those fields establish identity for reconciliation; they do not verify biological activity or authorize a route of use.
Development history and research status
CJC-1295 was investigated for lipodystrophy and growth-hormone deficiency and reached phase II clinical trials, but that development was discontinued upon the death of one of the trial subjects, and reference sources categorize it as an abandoned drug with no legal status. That history is stated here as documented regulatory fact, not as a claim about effects; the existence of past investigation does not establish that a third-party research material is an authorized drug product, equivalent to any study material, or suitable for human use.
Canadian and anti-doping regulatory context
Health Canada’s April 2026 public advisory on unauthorized injectable peptides names CJC-1295 among the products it identifies, and states that unauthorized drug products are illegal in Canada and have not been assessed for safety, efficacy, and quality by Health Canada. CJC-1295 is prohibited by the World Anti-Doping Agency — relevant to any research setting connected to sport.
The advisory is also explicit that a “research use only” label “does not make these products legal or exempt from regulatory requirements.” Vitatide’s research-use wording should be read the same way — a use boundary, not a claim of regulatory authorization — and determining whether a given procurement, possession, import, or use complies with applicable requirements remains the purchaser’s and the receiving laboratory’s responsibility.
Read the Health Canada public advisory
What a CoA can and cannot establish
A lot-linked Certificate of Analysis can report measurements such as chromatographic area percentage, observed mass, or other tests performed by the issuing laboratory, and its scope is limited to the sample, methods, and results stated on that document. Because CJC-1295 exists in more than one form, the documentation should make clear which form the lot is. The checks are otherwise the same:
- Match the compound, form, lot, and certificate identifier.
- Read the method and the actual measured value.
- Separate chromatographic purity from identity and potency.
- Do not treat a CoA as regulatory approval, sterility assurance, or a substitute for an end laboratory’s validated controls unless the document expressly supports that conclusion.
Procurement boundary for Canadian laboratories
Before ordering, review the canonical product page, the posted source record, destination restrictions, and the Research-Use-Only Acknowledgement. After receipt, identity reconciliation, storage, preparation, assay design, waste handling, and chain-of-custody remain the receiving laboratory’s responsibility.
For laboratory research use only. Not for human consumption, diagnostic, or therapeutic use. This article summarizes public regulatory and reference sources and is not legal or medical advice.